Feature | Cluster | Comparison | P-value |
---|---|---|---|
Breast cancer | |||
Her2/Neu status | Cluster 1–88.2% | Other tumors – 7.7% | < 0.0001 |
Hepatocellular carcinoma | |||
Hepatitis B | Cluster 2–38.4% | Other tumors – 18.6% | < 0.0001 |
Endometrial carcinoma | |||
Type II (serous) type | Cluster 1–32.4% | Other tumors – 5.2% | < 0.0001 |
Locoregional disease or recurrence | Cluster 1–8.6% | Other tumors – 2.2% | 0.004 |
Lung cancer | |||
Adenocarcinoma | Cluster 2–80.0% | Other tumors – 37.8% | < 0.0001 |
Squamous cell carcinoma | Cluster 4–73.6% | Other tumors – 34.2% | < 0.0001 |
Kidney clear cell carcinoma | |||
Gender | Cluster 1–92.9% female | Other tumors – 29.0% female | |
Longest dimension | Cluster 2–1.5 cm | Other tumors – 1.8 cm | < 0.0001 |
Histologic grade 3 or 4 | Cluster 3–69.0% | Other tumors – 41.5% | < 0.0001 |
Pathologic stage III or IV | Cluster 3–58.5% | Other tumors – 25.5% | < 0.0001 |
Thyroid carcinoma | |||
Gender | Cluster 3–35.4% male | Other tumors – 11.3% male | < 0.0001 |
Tall cell subtype | Cluster 1–17.2% | Other tumors – 5.03% | 0.0001 |
Follicular subtype | Cluster 3–27.7% | Other tumors – 10.5% | < 0.0001 |
Acute myeloid leukemia | |||
Gender | Cluster 1–100% female Cluster 3–81.5% male | Cluster 2–53.6% female | < 0.0001 |
Complex (> 3 distinct) cytogenetic abnormalities | Cluster 3–21.0% | Other tumors – 5.5% | 0.0025 |
Testicular cancer | |||
Seminoma subtype | Cluster 1–100% | Other tumors – 14.5% | < 0.0001 |
Embryonal carcinoma subtype | Cluster 2–94.6% | Other tumors – 20.6% | < 0.0001 |
Teratoma subtype | Cluster 3–84.0% | Other tumors – 14.7% | < 0.0001 |
Head and neck cancer | |||
HPV infection | Cluster 1–46.1% | Other tumors – 9.8% | 0.0001 |
Skin cutaneous melanoma | |||
Breslow depth | Cluster 1–4.8 cm | Other tumors – 7.6 cm | 0.0083 |
Brain cancer | |||
Glioblastoma | Cluster 3–100% | Other tumors – 0% | < 0.0001 |
Astrocytoma low-grade glioma | Cluster 2–53.0% Cluster 4–62.7% | Other tumors – 2.5% | < 0.0001 |
Non-astrocytoma low-grade glioma | Cluster 1–86.7% Cluster 5–97.0% | Other tumors – 29.1% | < 0.0001 |